Amelioration of Diabetes-induced Cognitive Deficits by GSK-3β Inhibition is Attributed to Modulation of Neurotransmitters and Neuroinflammation

Molecular Neurobiology

Volumn 50, Issue 2, 2014, Pages 390-405

  Datusalia, Ashok Kumar ^a   Sharma, Shyam Sunder ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Cognitive deficits; Glycogen synthase kinase 3 ; Neuroinflammation; Neurotransmitter; Type 2 diabetes

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 4 AMINOBUTYRIC ACID; ACETYLCHOLINESTERASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; GLUCOSE; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; HEMOGLOBIN A1C; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INTERLEUKIN 6; NEUROTRANSMITTER; STREPTOZOCIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; BEHAVIOR DISORDER; BODY WEIGHT; CHRONIC DISEASE; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FRONTAL CORTEX; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HIPPOCAMPUS; HOMEOSTASIS; INSULIN BLOOD LEVEL; LATENT PERIOD; LIPID DIET; LONG TERM CARE; LOW DRUG DOSE; MALE; MEMORY DISORDER; MENTAL PERFORMANCE; MILD COGNITIVE IMPAIRMENT; MORRIS WATER MAZE TEST; MOTOR PERFORMANCE; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PASSIVE AVOIDANCE TEST; PLACE PREFERENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REVIEW; SKILL; SPATIAL LEARNING; TREATMENT DURATION; Y-MAZE TEST; ANIMAL; ANTAGONISTS AND INHIBITORS; COGNITION DISORDERS; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; INFLAMMATION; METABOLISM; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; COGNITION DISORDERS; DIABETES MELLITUS, EXPERIMENTAL; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; INDOLES; INFLAMMATION; MALE; MALEIMIDES; NEUROTRANSMITTER AGENTS; NITRIC OXIDE SYNTHASE TYPE II; PROTEIN KINASE INHIBITORS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84911002848     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8632-x     Document Type: Review

References (68)

1. Alberti KGMM, Zimmet P (2013) Epidemiology: global burden of disease—where does diabetes mellitus fit in? Nat Rev Endocrinol 9(5):258–260. doi:10.1038/nrendo.2013.54
2. Guariguata L (2012) By the numbers: new estimates from the IDF Diabetes Atlas Update for 2012. Diabetes Res Clin Pract 98(3):524–525. doi:10.1016/j.diabres.2012.11.006
3. Bernstein CM, Stockwell MS, Gallagher MP, Rosenthal SL, Soren K (2013) Mental health issues in adolescents and young adults with type 1 diabetes prevalence and impact on glycemic control. Clin Pediatr 52(1):10–15. doi:10.1177/0009922812459950
4. Luchsinger JA (2012) Type 2 diabetes and cognitive impairment: linking mechanisms. J Alzheimers Dis 30:S185–S198. doi:10.3233/JAD-2012-111433
5. McCrimmon RJ, Ryan CM, Frier BM (2012) Diabetes and cognitive dysfunction. Lancet 379(9833):2291–2299. doi:10.1016/S0140-6736(12)60360-2
6. Priyadarshini M, Kamal MA, Greig NH, Realef M, Abuzenadah AM, Ga Chaudhary A, Damanhouri GA (2012) Alzheimers disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase. CNS Neurol Disord Drug Targets 11(4):482–489. doi:10.2174/187152712800792767
7. Profenno LA, Porsteinsson AP, Faraone SV (2010) Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 67(6):505–512. doi:10.1016/j.biopsych.2009.02.013
8. Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS, Baertlein L, Boeve BF, Tangalos EG, Ivnik RJ, Mielke MM (2013) Association of diabetes with amnestic and nonamnestic mild cognitive impairment. Alzheimers Dement. doi:10.1016/j.jalz.2013.01.001
9. Vagelatos NT, Eslick GD (2013) Type 2 diabetes as a risk factor for Alzheimer's disease: the confounders, interactions, and neuropathology associated with this relationship. Epidemiol Rev 35(1):152–160. doi:10.1093/epirev/mxs012
10. Kodl CT, Seaquist ER (2008) Cognitive dysfunction and diabetes mellitus. Endocr Rev 29(4):494–511. doi:10.1210/er.2007-0034
11. Farr SA, Yamada KA, Butterfield DA, Abdul HM, Xu L, Miller NE, Banks WA, Morley JE (2008) Obesity and hypertriglyceridemia produce cognitive impairment. Endocrinology 149(5):2628–2636. doi:10.1210/en.2007-1722
12. Geroldi C, Frisoni GB, Paolisso G, Bandinelli S, Lamponi M, Abbatecola AM, Zanetti O, Guralnik JM, Ferrucci L (2005) Insulin resistance in cognitive impairment: the InCHIANTI study. Arch Neurol 62(7):1067. doi:10.1001/archneur.62.7.1067
13. de la Monte SM (2009) Insulin resistance and Alzheimer's disease. BMB Rep 42(8):475
14. Cole AR (2013) Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia. FEBS J 280(21):5213–5227. doi:10.1111/febs.12407
15. King MK, Pardo M, Cheng Y, Downey K, Jope RS, Beurel E (2013) Glycogen synthase kinase-3 inhibitors: rescuers of cognitive impairments. Pharmacol Ther. doi:10.1016/j.pharmthera.2013.07.010
16. Takahashi-Yanaga F (2013) Activator or inhibitor? GSK-3 as a new drug target. Biochem Pharmacol 86(2):191–199. doi:10.1016/j.bcp.2013.04.022
17. Kaidanovich-Beilin O, Woodgett JR (2013) Glycogen synthase kinase-3 in neurological diseases. In: Mukai H (ed) Protein kinase technologies, vol 68, Neuromethods, vol 68. Springer, New York, pp 153–188
18. Mondragon-Rodriguez S, Perry G, Zhu X, Moreira PI, Williams S (2012) Glycogen synthase kinase 3: a point of integration in Alzheimer's disease and a therapeutic target? Int J Alzheimers Dis 2012:1–4. doi:10.1155/2012/276803
19. Phiel CJ, Wilson CA, Lee VM, Klein PS (2003) GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423(6938):435–439. doi:10.1038/nature01640
20. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20(1–2):27–39. doi:10.1093/emboj/20.1.27
21. Beurel E, Jope RS (2006) The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 79(4):173–189. doi:10.1016/j.pneurobio.2006.07.006
22. Hernandez F, Borrell J, Guaza C, Avila J, Lucas JJ (2002) Spatial learning deficit in transgenic mice that conditionally over-express GSK3beta in the brain but do not form tau filaments. J Neurochem 83(6):1529–1533. doi:10.1046/j.1471-4159.2002.01269.x
23. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P (2005) Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 52(4):313–320. doi:10.1016/j.phrs.2005.05.004
24. Guo W, Murthy AC, Zhang L, Johnson EB, Schaller EG, Allan AM, Zhao X (2012) Inhibition of GSK3β improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome. Hum Mol Genet 21(3):681–691
25. Dellu F, Fauchey V, Moal ML, Simon H (1997) Extension of a new two-trial memory task in the rat: influence of environmental context on recognition processes. Neurobiol Learn Mem 67(2):112–120. doi:10.1006/nlme.1997.3746
26. Kumar P, Kaundal RK, More S, Sharma SS (2009) Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease. Behav Brain Res 197(2):398–403. doi:10.1016/j.bbr.2008.10.010
27. D'Hooge R, De Deyn PP (2001) Applications of the Morris water maze in the study of learning and memory. Brain Res Rev 36(1):60–90. doi:10.1016/S0165-0173(01)00067-4
28. Lakshmana MK, Rao S, Dhingra NK, Ravikumar R, Meti BL, Raju TR (1998) Chronic (−) deprenyl administration increases dendritic arborization in CA3 neurons of hippocampus and AChE activity in specific regions of the primate brain. Brain Res 796(1):38–44. doi:10.1016/S0006-8993(98)00312-6
29. Rao BSS, Raju TR, Meti BL (1998) Self-stimulation of lateral hypothalamus and ventral tegmentum increases the levels of noradrenaline, dopamine, glutamate, and AChE activity, but not 5-hydroxytryptamine and GABA levels in hippocampus and motor cortex. Neurochem Res 23(8):1053–1059. doi:10.1023/A:1020703901794
30. Kumar A, Sharma SS (2010) NF-kappaB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem Biophys Res Commun 394(2):360–365. doi:10.1016/j.bbrc.2010.03.014
31. Schiffman HR, Lore R, Passafiume J, Neeb R (1970) Role of vibrissae for depth perception in the rat (Rattus norvegicus). Anim Behav 18:290–292
32. Biessels GJ, Koffeman A, Scheltens P (2006) Diabetes and cognitive impairment. J Neurol 253(4):477–482. doi:10.1007/s00415-005-0036-4
33. Jiang LY, Tang SS, Wang XY, Liu LP, Long Y, Hu M, Liao MX, Ding QL, Hu W, Li JC (2012) PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus. CNS Neurosci Ther 18(8):659–666. doi:10.1111/j.1755-5949.2012.00341.x
34. Rahigude A, Bhutada P, Kaulaskar S, Aswar M, Otari K (2012) Participation of antioxidant and cholinergic system in protective effect of naringenin against type-2 diabetes induced memory dysfunction in rats. Neuroscience 226:62–72. doi:10.1016/j.neuroscience.2012.09.026
35. Biessels GJ, Kerssen A, de Haan EHF, Kappelle LJ (2007) Cognitive dysfunction and diabetes: implications for primary care. Prim Care Diabetes 1(4):187–193. doi:10.1016/j.pcd.2007.10.002
36. Pipatpiboon N, Pratchayasakul W, Chattipakorn N, Chattipakorn SC (2012) PPARγ agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets. Endocrinology 153(1):329–338. doi:10.1210/en.2011-1502
37. Ryan CM, Freed MI, Rood JA, Cobitz AR, Waterhouse BR, Strachan MWJ (2006) Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care 29(2):345–351. doi:10.2337/diacare.29.02.06.dc05-1626
38. Zhao W-Q, Townsend M (2009) Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 1792(5):482–496. doi:10.1016/j.bbadis.2008
39. Zhao W-Q, Chen H, Quon MJ, Alkon DL (2004) Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol 490(1):71–81. doi:10.1016/j.ejphar.2004.02.045
40. Bradley CA, Sp P, Taghibiglou C, Nicolas CS, Whitcomb DJ, Bortolotto ZA, Kaang B-K, Cho K, Wang YT, Collingridge GL (2012) A pivotal role of GSK-3 in synaptic plasticity. Front Mol Neurosci 5:13–20. doi:10.3389/fnmol.2012.00013
41. Kaidanovich-Beilin O, Beaulieu J-M, Jope RS, Woodgett JR (2012) Neurological functions of the masterswitch protein kinase-GSK-3. Front Mol Neurosci 5:1–2. doi:10.3389/fnmol.2012.00048
42. Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol (Oxf) 65(4):391–426. doi:10.1016/S0301-0082(01)00011-9
43. Clodfelder-Miller B, De Sarno P, Zmijewska AA, Song L, Jope RS (2005) Physiological and pathological changes in glucose regulate brain Akt and glycogen synthase kinase-3. J Biol Chem 280(48):39723–39731. doi:10.1074/jbc.M508824200
44. King MR, Anderson NJ, Guernsey LS, Jolivalt CG (2013) Glycogen synthase kinase-3 inhibition prevents learning deficits in diabetic mice. J Neurosci Res 91:506–514. doi:10.1002/jnr.23192
45. Qu Z, Jiao Z, Sun X, Zhao Y, Ren J, Xu G (2011) Effects of streptozotocin-induced diabetes on tau phosphorylation in the rat brain. Brain Res 1383:300–306. doi:10.1016/j.brainres.2011.01.084
46. Zhang T, Pan B-S, Sun G-C, Sun X, Sun F-Y (2010) Diabetes synergistically exacerbates poststroke dementia and tau abnormality in brain. Neurochem Int 56(8):955–961. doi:10.1016/j.neuint.2010.04.003
47. Lonze BE, Ginty DD (2002) Function and regulation of CREB family transcription factors in the nervous system. Neuron 35(4):605–623. doi:10.1016/S0896-6273(02)00828-0
48. Kida S (2012) A functional role for CREB as a positive regulator of memory formation and LTP. Exp Neurobiol 21(4):136–140. doi:10.5607/en.2012.21.4.136
49. Mantamadiotis T, Lemberger T, Bleckmann SC, Kern H, Kretz O, Villalba AM, Fo T, Kellendonk C, Gau D, Kapfhammer J (2002) Disruption of CREB function in brain leads to neurodegeneration. Nat Genet 31(1):47–54. doi:10.1038/ng882
50. Grimes CA, Jope RS (2001) CREB DNA binding activity is inhibited by glycogen synthase kinase 3β and facilitated by lithium. J Neurochem 78(6):1219–1232. doi:10.1046/j.1471-4159.2001.00495.x
51. Tullai JW, Chen J, Schaffer ME, Kamenetsky E, Kasif S, Cooper GM (2007) Glycogen synthase kinase-3 represses cyclic AMP response element-binding protein (CREB)-targeted immediate early genes in quiescent cells. J Biol Chem 282(13):9482–9491. doi:10.1074/jbc.M700067200
52. Kuhad A, Bishnoi M, Tiwari V, Chopra K (2009) Suppression of NF-kappabeta signaling pathway by tocotrienol can prevent diabetes associated cognitive deficits. Pharmacol Biochem Behav 92(2):251–259. doi:10.1016/j.pbb.2008.12.012
53. Negi G, Kumar A, Sharma SS (2011) Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-kB and Nrf2 cascades. J Pineal Res 50(2):124–131. doi:10.1111/j.1600-079X.2010.00821.x
54. Yirmiya R, Goshen I (2011) Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 25(2):181–213. doi:10.1016/j.bbi.2010.10.015
55. Zhong H, Voll RE, Ghosh S (1998) Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1(5):661–671. doi:10.1016/S1097-2765(00)80066-0
56. Khandkar MA, Mukherjee E, Parmar DV, Katyare SS (1995) Alloxan-diabetes alters kinetic properties of the membrane-bound form, but not of the soluble form, of acetylcholinesterase in rat brain. Biochem J 307(Pt 3):647–649
57. Suhail M, Rizvi SI (1989) Erythrocyte membrane acetylcholinesterase in type 1 (insulin-dependent) diabetes mellitus. Biochem J 259(3):897–899
58. Kuhad A, Chopra K (2007) Curcumin attenuates diabetic encephalopathy in rats: behavioral and biochemical evidences. Eur J Pharmacol 576(1):34–42. doi:10.1016/j.ejphar.2007.08.001
59. Danbolt NC (2001) Glutamate uptake. Prog Neurobiol (Oxf) 65(1):1–105. doi:10.1016/S0301-0082(00)00067-8
60. Riedel G, Reymann KG (2003) Metabotropic glutamate receptors in hippocampal long term potentiation and learning and memory. Acta Physiol Scand 157(1):1–19. doi:10.1046/j.1365-201X.1996.484231000.x
61. Sickmann HM, Waagepetersen HSN, Schousboe A, Benie AJ, Bouman SD (2012) Brain glycogen and its role in supporting glutamate and GABA homeostasis in a type 2 diabetes rat model. Neurochem Int 60(3):267–275. doi:10.1016/j.neuint.2011.12.019
62. Sickmann HM, Waagepetersen HS, Schousboe A, Benie AJ, Bouman SD (2010) Obesity and type 2 diabetes in rats are associated with altered brain glycogen and amino-acid homeostasis. J Cereb Blood Flow Metab 30(8):1527–1537. doi:10.1038/jcbfm.2010.61
63. Dienel GA (2013) Astrocytic energetics during excitatory neurotransmission: what are contributions of glutamate oxidation and glycolysis? Neurochem Int 63(4):244–258. doi:10.1016/j.neuint.2013.06.01
64. Hwangbo Y, Kim JT, Kim EK, Khang AR, Oh TJ, Jang HC, Park KS, Kim SY, Lee HK, Cho YM (2012) Prevalence and clinical characteristics of recently diagnosed type 2 diabetes patients with positive anti-glutamic acid decarboxylase antibody. Diabetes Metab 36(2):136–143. doi:10.4093/dmj.2012.36.2.136
65. Brioni JD (2004) Role of GABA during the multiple consolidation of memory. Drug Dev Res 28(1):3–27. doi:10.1002/ddr.430280103
66. Cruz-Morales SE, Quirarte GL, Diaz del Guante MA, Prado-Alcala RA (1993) Effects of GABA antagonists on inhibitory avoidance. Life Sci 53(16):1325–1330. doi:10.1016/0024-3205(93)90578-Q
67. Flood JF, Morley JE, Roberts E (1992) Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it. Proc Natl Acad Sci U S A 89(5):1567–1571. doi:10.1073/pnas.89.5.1567
68. Gandhi GK, Ball KK, Cruz NF, Dienel GA (2010) Hyperglycaemia and diabetes impair gap junctional communication among astrocytes. ASN Neuro 2(2):e00030. doi:10.1042/AN20090048